1,172
Views
4
CrossRef citations to date
0
Altmetric
Drug Profile

Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus

Pages 603-612 | Published online: 10 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

André J. Scheen. (2016) Investigational insulin secretagogues for type 2 diabetes. Expert Opinion on Investigational Drugs 25:4, pages 405-422.
Read now
Carla Francés Artigas, Victoria Stokes, Garry D Tan & Michael J Theodorakis. (2015) Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice. Expert Opinion on Pharmacotherapy 16:10, pages 1417-1421.
Read now

Articles from other publishers (2)

Yasuo Terauchi, Yusuke Naito & Yukio Ikeda. (2016) Evaluation of unmet medical need among Japanese patients with type 2 diabetes mellitus and efficacy of Lixisenatide treatment among Asian type 2 diabetes mellitus patients. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 10:1, pages 23-28.
Crossref
Kazuhiro Eto, Yusuke Naito & Yutaka Seino. (2015) Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials. Diabetology & Metabolic Syndrome 7:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.